The Manufacturers Life Insurance Company Decreases Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

The Manufacturers Life Insurance Company lessened its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 108,548 shares of the medical equipment provider’s stock after selling 7,011 shares during the quarter. The Manufacturers Life Insurance Company owned 0.16% of Lantheus worth $8,715,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in LNTH. Farallon Capital Management LLC increased its holdings in Lantheus by 595.3% in the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock valued at $92,316,000 after buying an additional 1,269,900 shares in the last quarter. Swedbank AB acquired a new stake in shares of Lantheus in the 1st quarter worth approximately $26,346,000. Nomura Holdings Inc. increased its stake in Lantheus by 105.3% in the 4th quarter. Nomura Holdings Inc. now owns 20,678 shares of the medical equipment provider’s stock valued at $1,282,000 after purchasing an additional 407,507 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in Lantheus by 25.3% during the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock worth $121,867,000 after purchasing an additional 394,837 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Lantheus by 5.6% during the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after purchasing an additional 389,828 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Up 1.1 %

LNTH stock opened at $107.79 on Friday. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The stock has a market capitalization of $7.47 billion, a P/E ratio of 16.46 and a beta of 0.50. The company has a 50 day moving average price of $103.77 and a two-hundred day moving average price of $87.35. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. During the same quarter in the previous year, the company posted $1.40 earnings per share. The business’s revenue for the quarter was up 22.5% compared to the same quarter last year. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Insider Transactions at Lantheus

In related news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the transaction, the chief accounting officer now owns 62,216 shares of the company’s stock, valued at approximately $7,661,900.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the sale, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, President Paul Blanchfield sold 2,000 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares in the company, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,852 shares of company stock worth $3,922,001 in the last three months. Company insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on LNTH. Truist Financial cut their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Leerink Partners upped their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. B. Riley raised their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Redburn Atlantic assumed coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price on the stock. Finally, JMP Securities lowered their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $126.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.